Latest Cryogenics News

Page 2 of 2

Bluechiip Eyes 2025 Growth Amid Strategic Review and BioLife Partnership

Bluechiip Limited remains in ASX suspension as it finalises its 2024 audited accounts, while its ongoing Strategic Review and BioLife deal set the stage for a pivotal 2025 focused on revenue growth and cash-flow break-even.

Ada Torres

30 Jan 2025

Bluechiip Secures $750k BioLife Licensing Deal Amid Strategic Review

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.

Ada Torres

30 Jan 2025

Browse the archive

Full archive

Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026